Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Novel Quantitative Liver Steatosis Assessment Method With Ultrasound Harmonic Imaging
Zhang, Jingke , Huang, Chengwu , Tang, Shanshan , Liu, Hui , DeRuiter, Ryan M. , Petersen, Kendra E , Knoll, Kate M , Robinson, Kathryn, Watt, Kymberly D., Callstrom, Matthew R. , Chen, Shigao , Petersen, Kendra E. , Zhang, Jingke , Lok, U-Wai , Liu, Hui , DeRuiter, Ryan , Petersen, Kendra, Knoll, Kate, Watt, Kymberly, Callstrom, Matthew, Huang, Chengwu , Gong, Ping , Lok, U‐Wai , Robinson, Kathryn

Mayo Clinic

Journal of Ultrasound in Medicine | September 24, 2024 | Volume: 44 | Issue: 1 | Pages: 77-85

10.1002/jum.16582 | PMID 39315751 Get It

ObjectivesMetabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%–30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost‐effective, widely accessible, and precise biomarkers to evaluate liver steatosis. This study aims to assess and compare the diagnostic performance of a novel reference frequency method‐based ultrasound attenuation coefficient estimation (ACE) in both fundamental (RFM‐ACE‐FI) and harmonic (RFM‐ACE‐HI) imaging for detecting and grading liver steatosis.MethodsAn Institutional Review Board‐approved prospective study was carried out between December 2018 and October 2022. A total number of 130 subjects were enrolled in the study. The correlation between RFM‐ACE‐HI values and magnetic resonance imaging proton density fat fraction (MRI‐PDFF), as well as between RFM‐ACE‐FI values and MRI‐PDFF were calculated. The diagnostic performance of RFM‐ACE‐FI and RFM‐ACE‐HI was evaluated using receiver operating characteristic (ROC) curve analysis, as compared to MRI‐PDFF. The reproducibility of RFM‐ACE‐HI was assessed by interobserver agreement between two sonographers.ResultsA strong correlation was observed between RFM‐ACE‐HI and MRI‐PDFF, with R = 0.88 (95% confidence interval [CI]: 0.83–0.92; P < .001), while the correlation between RFM‐ACE‐FI and MRI‐PDFF was R = 0.65 (95% CI: 0.50–0.76; P < .001). The area under the ROC (AUROC) curve for RFM‐ACE‐HI in staging liver steatosis grades of S ≥ 1 and S ≥ 2 was 0.97 (95% CI: 0.91–0.99; P < .001) and 0.98 (95% CI: 0.93–1.00; P < .001), respectively, and 0.76 (95% CI: 0.65–0.85) and 0.80 (95% CI: 0.70–0.88) for RFM‐ACE‐FI, respectively. Great reproducibility was achieved for RFM‐ACE‐HI, with an interobserver agreement of R = 0.97 (95% CI: 0.94–0.99; P < .001).ConclusionsThe novel RFM‐ACE‐HI method offered high liver steatosis diagnostic accuracy and reproducibility, which has important clinical implications for early disease intervention and treatment evaluation.
A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19
Kashem, Mohammed A. , Loor, Gabriel , Emtiazjoo, Amir , Hartwig, Matthew G. , Raemdonck, Dirk Van , Calvelli, Hannah , Pena, A. Leon, Salan‐Gomez, Marcelo , Warnick, Michael, Villavicencio, Mauricio A. , Ius, F. , Salman, J. , Chandrashekaran, Satish, Machuca, Tiago , Sánchez, Pablo G. , Neyrinck, Arne , Huddleston, Stephen J. , Ceulemans, Laurens J. , D'Silva, Ethan , Ramamurthy, Uma , Shaffer, Andrew , Langer, Nathaniel B. , Toyoda, Yoshiya , Van Raemdonck, Dirk , Villavicencio, Mauricio, Salman, Jawad , Sanchez, Pablo G , Huddleston, Stephen , Osho, Asishana , Ceulemans, Laurens J , Zhao, Huaqing , Ghadimi, Kamrouz , Subramaniam, Kathirvel , Osho, Asishana A.

Mayo Clinic

Clinical Transplantation | September 24, 2024 | Volume: 38 | Issue: 9 | Pages: No page available

10.1111/ctr.15462 | PMID 39315691 Get It

ABSTRACTIntroductionLung transplantation has become increasingly utilized in patients with COVID‐19. While several single‐center and UNOS database studies have been published on lung transplants (LTs) for end‐stage lung disease (ESLD) from Coronavirus disease 2019 (COVID‐19), there is a lack of multi‐center and international data.MethodsThis is a multicenter analysis from 11 high‐volume lung transplant centers in the United States and Europe. Data were collected through the Multi‐Institutional ECLS Registry and stratified by ESLD due to COVID‐19 versus other etiologies. Demographics and clinical variables were compared using Chi‐square test and Fisher's exact test. Survival was assessed by Kaplan‐Meier curves and compared by log‐rank test with propensity score matching.ResultsOf 1606 lung transplant recipients, 46 (2.9%) were transplanted for ESLD from COVID‐19 compared to 1560 (97.1%) without a history of COVID‐19. Among COVID‐19 patients, 30 (65.2%) had COVID‐19‐associated ARDS and 16 (34.8%) had post‐COVID‐19 fibrosis. COVID‐19 patients had higher lung allocation scores (78.0 vs. 44.4, p < 0.0001), had severely limited functional status (37.0% vs. 2.9%, p < 0.0001), had higher preoperative ECMO usage (65.2% vs. 5.4%, p < 0.0001), and spent less time on the waitlist (32 vs. 137 days, p < 0.0001). A 30‐day survival was comparable between COVID‐19 and non‐COVID‐19 patients before (100% vs. 98.7%, p = 0.39) and after propensity matching (p = 0.15).ConclusionsPatients who received LTs due to COVID‐19 had short‐term survival comparable to that of patients without COVID‐19. Our findings support the idea that lung transplantation should be considered for select patients with ESLD due to COVID‐19.
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152

10.1002/alz.14250 | PMID 39316411 Get It

AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
Multiplexed Assays of Variant Effect and Automated Patch Clamping Improve KCNH2 -LQTS Variant Classification and Cardiac Event Risk Stratification
O’Neill, Matthew J. , Ng, Chai‐Ann , Aizawa, Takanori , Sala, Luca , Bains, Sahej , Winbo, Annika , Ullah, Rizwan , Shen, Qianyi, Tan, Chek-Ying, Kozek, Krystian A. , Vanags, Loren , Mitchell, Devyn , Shen, Alex , Kashiwa, Asami , Musu, Giulia , Bos, J. Martijn , Giudicessi, John R. , Bledsoe, Xavier , Gamazon, Eric R. , Glazer, Andrew M. , Roden, Dan M. , Stiles, Rachael, Agee, Taylor , Johnson, Christopher N. , Ackerman, Michael J. , Ohno, Seiko , Vandenberg, Jamie I. , Kroncke, Brett M. , Kozek, Krystian , Mitchell, Devyn W , Wada, Yuko , Kashiwa, Asami , Crotti, Lia , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel Almeida Lopes , Bos, Johan M , Giudicessi, J R , Bledsoe, Xavier , Lancaster, Megan C , Glazer, Andrew M , Knollmann, Bjorn C , Salem, Joe-Elie , Earle, Nikki , Agee, Taylor , Johnson, Christopher N , Horie, Minoru , Skinner, Jonathan R , Ackerman, Michael J , Schwartz, Peter J. , Ohno, Seiko , Vandenberg, Jamie I , Sala, Luca , Bains, Sahej , Wada, Yuko , Dagradi, Federica , Spazzolini, Carla , Neves, Raquel , Roden, Dan M. , Weile, Jochen , Roth, Frederick P. , Salem, Joe‐Elie , Skinner, Jonathan R.

Mayo Clinic

Circulation | September 24, 2024 | Volume: 150 | Issue: 23 | Pages: 1869-1881

10.1161/circulationaha.124.069828 | PMID 39315434 Get It

BACKGROUND: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by KCNH2 . Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance. Here we sought to test whether variant-specific information, primarily from high-throughput functional assays, could improve both classification and cardiac event risk stratification in a large, harmonized cohort of KCNH2 missense variant heterozygotes. METHODS: We quantified cell-surface trafficking of 18 796 variants in KCNH2 using a multiplexed assay of variant effect (MAVE). We recorded KCNH2 current density for 533 variants by automated patch clamping. We calibrated the strength of evidence of MAVE data according to ClinGen guidelines. We deeply phenotyped 1458 patients with KCNH2 missense variants, including QTc, cardiac event history, and mortality. We correlated variant functional data and Bayesian long QT syndrome penetrance estimates with cohort phenotypes and assessed hazard ratios for cardiac events. RESULTS: Variant MAVE trafficking scores and automated patch clamping peak tail currents were highly correlated (Spearman rank-order ρ=0.69; n=433). The MAVE data were found to provide up to pathogenic very strong evidence for severe loss-of-function variants. In the cohort, both functional assays and Bayesian long QT syndrome penetrance estimates were significantly predictive of cardiac events when independently modeled with patient sex and corrected QT interval (QTc); however, MAVE data became nonsignificant when peak tail current and penetrance estimates were also available. The area under the receiver operator characteristic curve for 20-year event outcomes based on patient-specific sex and QTc (area under the curve, 0.80 [0.76–0.83]) was improved with prospectively available penetrance scores conditioned on MAVE (area under the curve, 0.86 [0.83–0.89]) or attainable automated patch clamping peak tail current data (area under the curve, 0.84 [0.81–0.88]). CONCLUSIONS: High-throughput KCNH2 variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous KCNH2 missense variants.
Arthrodesis as Salvage for Failed Metacarpophalangeal Arthroplasty
Rode, Matthew M. , Wu, Kitty Y. , Welling, Benjamin D., Rizzo, Marco , Rode, Matthew , Welling, Benjamin D

Mayo Clinic

HAND | September 23, 2024 | Volume: 20 | Issue: 8 | Pages: 1259-1264

10.1177/15589447241279589 | PMID 39308183 Get It

Background: Surgical management of failed metacarpophalangeal (MCP) arthroplasties includes revision arthroplasty and arthrodesis. The purpose of this study was to review the indications and outcomes of arthrodesis as a salvage procedure for failed MCP arthroplasties. Methods: This was a retrospective cohort study of all patients undergoing salvage MCP arthrodesis at a single institution from 1990 to 2020. Patient charts were reviewed for patient demographics, indication for salvage, surgical technique, revision rate, and time to radiographic union. Patient-reported outcomes, including the Michigan Hand Outcomes Questionnaire and an MCP-specific questionnaire detailing pain, functional, appearance, and patient satisfaction, were also collected. Results: Eleven digits in 9 patients (6 women, 3 men, median age of 66) with median 36-month follow-up were included. The majority (91%) of patients also had concomitant soft tissue deformities, including joint contractures, extension lag, and collateral ligament insufficiency. The overall revision rate following arthrodesis was 45% with 3 digits requiring one revision each, and 2 digits undergoing 3 revisions. The overall union rate was 91% with median time to union of 4 months from most recent arthrodesis. Patient-reported outcomes obtained from 4 patients demonstrated improvements in pain and function. Conclusion: Despite a high revision rate of 45%, salvage MCP arthrodesis following arthroplasty has a high eventual union rate of 91% and is associated with improved pain and function based on 4 patients’ experiences. Arthrodesis as a salvage procedure for failed MCP arthroplasties should be considered in patients with persistent joint instability and functionally limiting soft tissue deformities.
Tolerability and Outcomes for Treatment of Older Myxoid Liposarcoma Population
Coombs, Reilly A. , Thangaiah, Judith Jebastin, Okuno, Scott H. , Houdek, Matthew T. , Xu‐Welliver, Meng , Ho, Thanh P. , Jebastin Thangaiah, Judith, Okuno, Scott , Houdek, Matthew T , Xu-Welliver, Meng , Ho, Thanh P , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Cancers | September 23, 2024 | Volume: 16 | Issue: 18 | Pages: 3233

10.3390/cancers16183233 | PMID 39335204 Get It

Background: Myxoid liposarcoma predominantly affects young and middle-aged individuals, and little is known regarding treatment tolerability and outcomes in older patients. This study aims to better understand this older patient population. Methods: This single institution retrospective study included patients aged 70 years and older with localized (non-metastatic) myxoid liposarcoma. Results: Sixteen patients were included. The median age was 75 years, and 9 (56%) were female. Fourteen (88%) were extremity tumors and two (12%) were trunk. The median tumor size was 10.4 cm (range, 3.6 to 28 cm). Five (31%) tumors had a round cell component. All patients had surgery. Fourteen (88%) had perioperative radiation, and three (19%) had perioperative chemotherapy. One patient had postoperative infection, and one patient had neutropenic fever from preoperative chemotherapy. The median follow up from surgery was 6.3 years. Eight (50%) patients died from MLPS. The median relapse-free survival and overall survival were 34 months and 75 months, respectively. Conclusions: Most older patients with localized MLPS received perioperative radiation therapy with surgery, and few serious toxicities were reported. Even with treatment, half of the patients relapsed.
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Shirian, Jason , Hockla, Alexandra , Gleba, Justyna J., Coban, Matt , Rotenberg, Naama, Strik, Laura M., Demirer, Aylin Alasonyalılar , Pawlush, Matt L., Copland, John A. , Radisky, Evette S. , Shifman, Julia M. , Trynda, Justyna , Pawlush, Matthew L. , Alasonyalilar Demirer, Aylin , Pawlush, Matthew L , Coban, Mathew A , Shifman, Julia M , Gleba, Justyna , Radisky, Evette S

Mayo Clinic

Biomolecules | September 23, 2024 | Volume: 14 | Issue: 9 | Pages: 1187

10.3390/biom14091187 | PMID 39334953 Get It

Matrix metalloproteinases (MMPs) are significant drivers of many diseases, including cancer, and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties for drug candidates, such as complete MMP inhibition, low toxicity, low immunogenicity, and high tissue permeability. However, a major challenge with TIMPs is their rapid clearance from the bloodstream due to their small size. This study explores a method for extending the plasma half-life of the N-terminal domain of TIMP2 (N-TIMP2) by appending it with a long, intrinsically unfolded tail containing Pro, Ala, and Thr (PATylation). We designed and produced two PATylated N-TIMP2 constructs with tail lengths of 100 and 200 amino acids (N-TIMP2-PAT100 and N-TIMP2-PAT200). Both constructs demonstrated higher apparent molecular weights and retained high inhibitory activity against MMP-9. N-TIMP2-PAT200 significantly increased plasma half-life in mice compared to the non-PATylated variant, enhancing its therapeutic potential. PATylation offers distinct advantages for half-life extension, such as fully genetic encoding, monodispersion, and biodegradability. It can be easily applied to N-TIMP2 variants engineered for high affinity and selectivity toward individual MMPs, creating promising candidates for drug development against MMP-related diseases.
Abstract B032: Advancing the science of cancer in Latinos conference
Jones, Rebecca T., Camargo, M. Constanza , Colón‐Otero, Gerardo , Despres, Cliff , Mendoza, Martín, Recio‐Boiles, Alejandro , Segarra-Vázquez, Barbara , Stanford, Sandi, Trapido, Edward , Orozco, Nicolette M, Ramirez, Amelie G , Banegas, Matthew P. , Fejerman, Laura , Lynce, Filipa , Moreno, Patricia I. , Stern, Mariana Carla , Tossas, Katherine Y.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B032-B032

10.1158/1538-7755.disp24-b032 Get It

Abstract Cancer is the leading cause of mortality within the Latino population. Projections suggest a 142% increase in cancer incidence among Latinos over the next two decades. This trend is concerning given that Latinos, the largest minority group in the United States, are expected to constitute at least 28% of the nation's populace by 2060. To address the need for enhanced comprehension of these trends and to identify equitable interventions targeting Latino health disparities, the Institute of Health Promotion Research and the Mays Cancer Center jointly established the biennial Advancing the Science of Cancer in Latinos (ASCL) Conference. The fourth ASCL Conference convened in San Antonio, TX from February 21-23, 2024. The conference objectives were twofold: 1) Examine the intersection of health equity and biological underpinnings in cancer control, prevention, and treatment; and 2) Foster collaborative initiatives among attendees aimed at addressing cancer-related health disparities within the Latino community. The 2024 conference attracted 286 participants compared to 251 attendees in 2022, encompassing guest speakers, researchers, physicians, healthcare professionals, patient advocates, researchers, and students. It comprised 23 sessions (3 keynotes, 6 plenaries, 6 breakouts, 3 general sessions, 1 special session, 1 lunch panel session) featuring insights from 51 speakers, alongside a poster session highlighting 80 research abstracts and a rapid-fire session tailored for early-career investigators. Sessions encompassed multiple topics relevant to Latino cancer research, spanning health disparities, clinical trials, survivorship, patient advocacy, climate change impacts on cancer, precision medicine, health policy and social determinants of health. A post-conference survey from a cohort of 48 respondents underscored high levels of satisfaction, with 90% expressing pronounced contentment regarding the conference experience, compared to 85% in 2022. Moreover, nearly all respondents (98%) rated the relevance of conference content to Latino cancer science as excellent, with 93% regarding the conference as an exceptional platform for information exchange, compared to 79% in 2022. Impressions regarding session quality were overwhelmingly positive, with 90% of respondents indicating a high level of satisfaction, and all survey respondents acknowledging the objectivity, balance, and absence of commercial bias in the session content. Our results showed that the resounding positivity in attendee feedback reflects the conference's success in fostering meaningful engagement among researchers committed to alleviating Latino cancer health disparities. The ASCL conference facilitated an understanding of cultural nuances and barriers specific to the Latino community, stimulating collaborative efforts aimed at enhancing Latino health outcomes. Overall, this retrospective analysis affirms the conference's success in achieving its stipulated objectives and underscores the need of having consistently coordinated research endeavors to reduce Latino health disparities. Citation Format: Amelie G. Ramirez, Rebecca T. Jones, Matthew P. Banegas, Maria C Camargo, Gerardo Colon-Otero, Cliff Despres, Laura Fejerman, Filipa Lynce, Martin Mendoza, Patricia I. Moreno, Alejandro Recio-Boiles, Barbara Segarra-Vazquez, Sandi Stanford, Mariana Stern, Katherine Y. Tossas, Edward J. Trapido, Nicolette M Orozco. Advancing the science of cancer in Latinos conference [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B032.
Comparative Assessment of Otolaryngology Knowledge Among Large Language Models
Merlino, Dante J. , Saieed, George, Abel, Kathryn M. Van , Archibald, David, Ator, Gregory A., Carlson, Matthew L. , Brufau, Santiago R, Van Abel, Kathryn M , Carlson, Matthew L , Romero‐Brufau, Santiago , Saieed, George , Price, Daniel L. , Archibald, David J.

Mayo Clinic

The Laryngoscope | September 21, 2024 | Volume: 135 | Issue: 2 | Pages: 629-634

10.1002/lary.31781 | PMID 39305216 Get It

ObjectiveThe purpose of this study was to evaluate the performance of advanced large language models from OpenAI (GPT‐3.5 and GPT‐4), Google (PaLM2 and MedPaLM), and an open source model from Meta (Llama3:70b) in answering clinical test multiple choice questions in the field of otolaryngology—head and neck surgery.MethodsA dataset of 4566 otolaryngology questions was used; each model was provided a standardized prompt followed by a question. One hundred questions that were answered incorrectly by all models were further interrogated to gain insight into the causes of incorrect answers.ResultsGPT4 was the most accurate, correctly answering 3520 of 4566 questions (77.1%). MedPaLM correctly answered 3223 of 4566 (70.6%) questions, while llama3:70b, GPT3.5, and PaLM2 were correct on 3052 of 4566 (66.8%), 2672 of 4566 (58.5%), and 2583 of 4566 (56.5%) questions. Three hundred and sixty‐nine questions were answered incorrectly by all models. Prompts to provide reasoning improved accuracy in all models: GPT4 changed from incorrect to correct answer 31% of the time, while GPT3.5, Llama3, PaLM2, and MedPaLM corrected their responses 25%, 18%, 19%, and 17% of the time, respectively.ConclusionLarge language models vary in their understanding of otolaryngology‐specific clinical knowledge. OpenAI's GPT4 has a strong understanding of core concepts as well as detailed information in the field of otolaryngology. Its baseline understanding in this field makes it well‐suited to serve in roles related to head and neck surgery education provided that the appropriate precautions are taken and potential limitations are understood.Level of EvidenceNA Laryngoscope, 135:629–634, 2025
Efficacy of Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) a Treatment for Cancer-related Cognitive Impairment (CRCI): A Randomized Controlled Trial
Reich, Richard R. , Rodriguez, Carmen S., Nguyen, Anh , Meng, Hongdao , Tinsley, Sara , Hueluer, Gizem, Donovan, Kristine A. , Bornstein, Elizabeth, Nidamanur, Sreenidhi, Padgett, Lynne, Lucas, Jean M., Fonseca, Tamela , Joshi, Anisha, Lin, Katherine, Goodman, Matthew , Hülür, Gizem , Tinsley, Sara , Hueluer, Gizem , Lengacher, Cecile A. , Park, Jong Y. , Moscoso, Manolete S. , Kiluk, John V. , Kip, Kevin E.

Mayo Clinic

Journal of Integrative and Complementary Medicine | September 18, 2024 | Volume: 31 | Issue: 1 | Pages: 75-91

10.1089/jicm.2024.0184 | PMID 39291332 Get It

Introduction: The Mindfulness-Based Stress Reduction (MBSR) Program for breast cancer survivors (BCS) is designed to enhance cognitive training through formal and informal meditational practices. This randomized clinical trial (RCT) aimed to evaluate if BCS assigned to either the MBSR(BC), Breast Cancer Education Support (BCES), or Usual Care (UC) regimens experienced greater improvements at 6, 12, and 26 weeks on objective and subjective cognitive performance. Methods: BCS ( n = 212) randomized to a three-group RCT: MBSR(BC) ( n = 91), BCES ( n = 90), or UC ( n = 31) were assessed on cognitive performance and symptoms at baseline, 6, 12, and 26 weeks. Linear mixed models were fit to evaluate the effects of the MBSR(BC) program, hypothesizing ordered effect improvements: (MBSR[BC] highest, BCES intermediate, UC lowest) along with baseline characteristics evaluated as moderators. Results: Of the BCS (mean age of 57), 73% were White, and non-Hispanic, and 77% received both chemotherapy (CT) and radiation. Cognitive performance improved in all groups. Although there were no statistically significant between-group differences in cognitive outcomes, significant symptom reductions occurred for the MBSR(BC) group ( p = 0.003). Within-group effect size analysis at 26 weeks showed substantial improvements in all three groups (effect sizes >0.50) in subjective impairments and quality of life (effect size >0.50) and objective measures of cognitive performance. MBSR(BC) showed the largest within-group effect size in the reduction of fatigue (effect size = 0.81). Effect sizes occurred in the hypothesized direction for 10 of the 18 outcomes. Discussion: Although the MBSR(BC) program did not show significant differences in cognitive performance compared with BCES and UC, all groups improved and reductions in fatigue were beneficial for MBSR(BC). Results suggest that cognitive performance may improve after CT over time considering one’s natural history. Furthermore, BCS enrolled in RCTs may be more motivated to improve their health status (NCT02786797).